Palatin Technologies Inc. 2025年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 PALATIN TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) (609)495‑2200(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934, as amended during the preceding 12 months (or for such shorter period that the registrant was required to file Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller Large accelerated filerNon-accelerated filerEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date (May14, 2025):46,479,861 PART I – FINANCIAL INFORMATIONItem 1. Financial Statements (Unaudited) PART II – OTHER INFORMATION Table of Contents Special Note Regarding Forward-Looking Statements In this Quarterly Report on Form 10-Q (this “Quarterly Report”) references to “we,” “our,” “us,” the “Company” or “Palatin” meanPalatin Technologies, Inc. and its subsidiary. Statements in this Quarterly Report, as well as oral statements that may be made by us or by our officers, directors, or employeesacting on our behalf, that are not historical facts constitute “forward-looking statements,” which are made pursuant to the safe harborprovisions of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The forward-looking statements ·our significant operating losses since our inception and our need to obtain additional financing has caused management todetermine there is substantial doubt regarding our ability to continue as a going concern; ·our ability to obtain additional financing on terms acceptable to us, or at all, including unavailability of funds or delays inreceiving funds as a result of economic disruptions; ·our expectation that we will incur losses for the foreseeable future and may never achieve or maintain profitability; our business, financial condition, and results of operations may be adversely affected by increases in costs of and delays inconducting human clinical trials and the performance of our contractors and suppliers, reduction in our productivity or the ·whether Cosette Pharmaceuticals, Inc. (“Cosette”), which acquired our product Vyleesi® (the trade name for bremelanotidefor treatment of hyperactive sexual desire disorder in premenopausal women) in December 2023, will have sufficient sales ·the results of clinical trials with our late-stage products, including co-administration of bremelanotide with tirzepatide, aGLP-1 agonist for treatment of obesity, which entered Phase 2 in the second quarter of calendar year 2024 with toplineresults announced in March 2025, in which co-administration demonstrated an increased weight loss over tirzepatidealone; PL9643, an ophthalmic peptide solution for dry eye disease (“DED”), which completed a first Phase 3 clinical trialswith top line results announced from the Phase 3 clinical trial in the first quarter of calendar year 2024 and which hasconcluded a positive Type C meeting with the FDA and can, depending on financial resources and product development ·estimates of our expenses, future revenue and capital requirements; ·our ability to achieve profitability; ·our ability to advance product candidates into, and successfully complete, clinical trials; ·the initiation, timing, progress and results of future preclinical studies and clinical trials, and our research and developmentprograms; ·the timing or likelihood of regulatory filings and approvals; Table of Contents ·our expectations regarding the clinical efficacy and utility of our melanocortin agonist product candidates for treatment ofinflammatory and autoimmune related diseases and disorders, including ocular indications;·our ability to compete with other products and technologies treating the same or similar indications as